2 research outputs found
Novel Huprine Derivatives with Inhibitory Activity toward β-Amyloid Aggregation and Formation as Disease-Modifying anti-Alzheimer Drug Candidates
A new family of dual binding site acetylcholinesterase (AChE)
inhibitors has been designed, synthesized, and tested for their
ability to inhibit AChE, butyrylcholinesterase (BChE), AChE-induced
and self-induced b-amyloid (Ab) aggregation and b-secretase
(BACE-1), and to cross the blood–brain barrier. The new
heterodimers consist of a unit of racemic or enantiopure huprine
Y or X and a donepezil-related 5,6-dimethoxy-2-[(4-piperidinyl)
methyl]indane moiety as the active site and peripheral site
to mid-gorge-interacting moieties, respectively, connected
through a short oligomethylene linker. Molecular dynamics
simulations and kinetics studies support the dual site binding
to AChE. The new heterodimers are potent inhibitors of
human AChE and moderately potent inhibitors of human
BChE, AChE-induced and self-induced Ab aggregation, and
BACE-1, and are predicted to be able to enter the central nervous
system (CNS), thus constituting promising multitarget anti-
Alzheimer drug candidates with the potential to modify the
natural course of this disease.Financial support from the Ministerio de Ciencia e InnovaciĂłn
(CTQ2008-03768/PPQ, SAF2009-10553, SAF2009-13093, SAF2006-
01249, SAF2008-05595), Generalitat de Catalunya (2005-
SGR00180, 2009-SGR00249), Instituto de Salud Carlos III
(PI080400), University of Bologna (RFO), MIUR (PRIN 2007), and
COST D34, and a fellowship for C.G. (IBUB) are acknowledged.Peer reviewe
Novel Huprine Derivatives with Inhibitory Activity toward β-Amyloid Aggregation and Formation as Disease-Modifying Anti-Alzheimer Drug Candidates
A new family of dual binding site acetylcholinesterase (AChE)
inhibitors has been designed, synthesized, and tested for their
ability to inhibit AChE, butyrylcholinesterase (BChE), AChE-induced
and self-induced b-amyloid (Ab) aggregation and b-secretase
(BACE-1), and to cross the blood–brain barrier. The new
heterodimers consist of a unit of racemic or enantiopure huprine
Y or X and a donepezil-related 5,6-dimethoxy-2-[(4-piperidinyl)
methyl]indane moiety as the active site and peripheral site
to mid-gorge-interacting moieties, respectively, connected
through a short oligomethylene linker. Molecular dynamics
simulations and kinetics studies support the dual site binding
to AChE. The new heterodimers are potent inhibitors of
human AChE and moderately potent inhibitors of human
BChE, AChE-induced and self-induced Ab aggregation, and
BACE-1, and are predicted to be able to enter the central nervous
system (CNS), thus constituting promising multitarget anti-
Alzheimer drug candidates with the potential to modify the
natural course of this disease.Financial support from the Ministerio de Ciencia e InnovaciĂłn
(CTQ2008-03768/PPQ, SAF2009-10553, SAF2009-13093, SAF2006-
01249, SAF2008-05595), Generalitat de Catalunya (2005-
SGR00180, 2009-SGR00249), Instituto de Salud Carlos III
(PI080400), University of Bologna (RFO), MIUR (PRIN 2007), and
COST D34, and a fellowship for C.G. (IBUB) are acknowledged.Peer reviewe